Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Class of 2025
Hammarskjold High School
Superior Collegiate and Vocational Institute
Westgate Collegiate & Vocational Institute
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by GENENTA SCIENCE SPA
Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals
July 01, 2025
From
GENENTA SCIENCE SPA
Via
GlobeNewswire
Tickers
GNTA
Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar
April 15, 2025
From
GENENTA SCIENCE SPA
Via
GlobeNewswire
Tickers
GNTA
Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates
March 19, 2025
From
GENENTA SCIENCE SPA
Via
GlobeNewswire
Tickers
GNTA
Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing
January 09, 2025
From
GENENTA SCIENCE SPA
Via
GlobeNewswire
Tickers
GNTA
Genenta’s CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”
October 23, 2024
From
GENENTA SCIENCE SPA
Via
GlobeNewswire
Tickers
GNTA
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
October 02, 2024
From
GENENTA SCIENCE SPA
Via
GlobeNewswire
Tickers
GNTA
Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider
May 06, 2024
From
GENENTA SCIENCE SPA
Via
GlobeNewswire
Tickers
ARYD
GNTA
SQZ
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
February 08, 2024
From
GENENTA SCIENCE SPA
Via
GlobeNewswire
Tickers
GNTA
Genenta to Present at Upcoming Scientific and Investor Conferences
September 06, 2023
From
GENENTA SCIENCE SPA
Via
GlobeNewswire
Tickers
GNTA
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments
July 28, 2023
From
GENENTA SCIENCE SPA
Via
GlobeNewswire
Tickers
GNTA
The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma
June 29, 2023
From
GENENTA SCIENCE SPA
Via
GlobeNewswire
Tickers
GNTA
Genenta to Provide Update on Lead Product Temferon™
May 16, 2023
From
GENENTA SCIENCE SPA
Via
GlobeNewswire
Tickers
GNTA
Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing
April 26, 2023
From
GENENTA SCIENCE SPA
Via
GlobeNewswire
Tickers
GNTA
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.